Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
September 21, 2017 09:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
September 10, 2017 11:45 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
September 10, 2017 04:45 ET
|
Five Prime Therapeutics, Inc.
Objective response rate of 48% and six-month disease control rate of 81% in patients at or below the maximum tolerated dose level; progression free survival of 7.4 monthsProgression-free survival...
Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
September 01, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
Objective response rate of 48% and disease control rate of 100% in patients at or below the maximum tolerated dose levelMedian progression free survival of 7.4 months SOUTH SAN FRANCISCO, Calif.,...
Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress
August 29, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research
August 17, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces Second Quarter 2017 Results and Provides Business Update
August 08, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8
July 26, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
July 17, 2017 16:10 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
June 21, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...